[Two cases of appearance of a new intrapulmonary lesion during antituberculous chemotherapy in tuberculous pleuritis].
We encountered two cases of infected primary complex in which a new intrapulmonary lesion appeared during antituberculous chemotherapy with RFP and INH. These were from 19 cases of tuberculous pleuritis which we treated in the past seven years. In the first case, the intrapulmonary lesion appeared 1 month after the initiation of antituberculous chemotherapy and disappeared at 4 months when the same chemotherapy was continued. In the second case, the lesion appeared 4 months after antituberculous chemotherapy was begun and disappeared at 13 months in the same manner. No particular abnormalities in clinical symptoms or laboratory findings were observed when the new intrapulmonary lesion appeared. In neither case had the lesion been hidden behind pleural effusion. The following causes were been thought to be responsible for the phenomenon rather than the so called initial reversible roentogenographic progression; In the first case, steroid therapy had been used for a short time, and in the other case, dose of antituberculous drugs had been reduced due to a drug allergy.
Kobashi
Y
Y
Department of Medicine, Kawasaki Hospital Kawasaki Medical School, Okayama, Japan.
Adachi
M
M
Kimura
M
M
Matsushima
T
T
D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D001999:Bronchoscopy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008168:Lung / Q000473:pathology*; D008297:Male; D012293:Rifampin / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D014396:Tuberculosis, Pleural / Q000188:drug therapy* / Q000473:pathology
D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin